- Home
- ECPG vs ELVN Comparison
ECPG vs ELVN Comparison
Compare ECPG & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECPG | ELVN |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ECPG | ELVN |
|---|---|---|
| Price | $55.21 | $16.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $59.50 | $41.00 |
| AVG Volume (30 Days) | 241.6K | ★ 804.7K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,560,869,000.00 | N/A |
| Revenue This Year | $32.56 | N/A |
| Revenue Next Year | $3.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.52 | N/A |
| 52 Week Low | $26.45 | $13.30 |
| 52 Week High | $56.67 | $25.37 |
Technical Indicators
Market Signals| Indicator | ECPG | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 64.12 | 36.31 |
| Support Level | $53.95 | $15.88 |
| Resistance Level | $55.72 | $18.05 |
| Average True Range (ATR) | 1.48 | 1.31 |
| MACD | -0.20 | -0.18 |
| Stochastic Oscillator | 63.72 | 6.41 |
Price Performance
Historical ComparisonAbout ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.